GlassScriptPhysician profile
Yvette Scharf
NPI 1417474164
$4,456.92
in general payments reported to CMS, 2019-2025
30 companies · $785 in 2025
The $785 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,112 · 2022: $947 · 2023: $840 · 2024: $773 · 2025: $785.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,383 · Education: $15.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,382.94 |
| Education | $15.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,022.28 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $525.66 | 2021-2025 | Mounjaro, Emgality, Reyvow |
| Abbvie INC. | $487.85 | 2021-2025 | |
| Amgen INC. | $456.43 | 2021-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $346.75 | 2021-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $332.50 | 2021-2025 | |
| Mylan Specialty L.P. | $279.97 | 2021-2024 | Yupelri |
| Otsuka America Pharmaceutical, INC. | $113.29 | 2022-2025 | Rexulti |
| Axsome Therapeutics, INC. | $100.75 | 2025 | Auvelity |
| Astrazeneca Pharmaceuticals LP | $94.49 | 2021-2024 | Breztri, Airsupra |
| Exact Sciences Corporation | $67.28 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $67.23 | 2021-2023 | Arexvy, Shingrix |
| Viatris Specialty LLC | $67.05 | 2025 | Yupelri |
| Esperion Therapeutics, INC. | $56.58 | 2021 | |
| Janssen Pharmaceuticals, INC | $54.85 | 2021-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $42.94 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $39.01 | 2022 | |
| Acadia Pharmaceuticals INC | $33.49 | 2025 | Daybue |
| Astellas Pharma US INC | $31.77 | 2021 | |
| Horizon Therapeutics Plc | $29.09 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $27.99 | 2023-2025 | Gvoke Hypopen |
| Novartis Pharmaceuticals Corporation | $27.52 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $26.83 | 2024-2025 | Austedo Xr, Austedo Xr |
| Kowa Pharmaceuticals America, INC. | $25.96 | 2021 | |
| Inspire Medical Systems, INC. | $19.75 | 2024 | Inspire |
| Lundbeck LLC | $18.95 | 2025 | Rexulti |
| Dexcom, INC. | $18.58 | 2022 | |
| Currax Pharmaceuticals LLC | $15.05 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $14.91 | 2023 | Inpefa |
| Pfizer INC. | $12.12 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yvette Scharf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.